Responses
Emerging technologies, pharmacology and therapeutics
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.